EUVIMEDOpdag EUVIMED
Multizentrische StudieOpen access · CC BY-NC-ND 4.0

Use and misuse of domperidone in patients living with Parkinson disease in France

Edouard Januel iD, Jean Christophe Corvol, Philippe Remy, Wassilios G Meissner, Claire Thiriez, Aymeric Lanore, Cecilia Bonnet, Jean-Philippe Azulay, Caroline Giordana, David Maltete, Solene Frismand, Christine Tranchant and 10 more

Fundamental & Clinical Pharmacology · 2025

DOI: 10.1111/fcp.70002 ↗

At a glance

Multizentrische Studie in Fundamental & Clinical Pharmacology, 2025. Written by Edouard Januel and 21 co-authors. Institution: Département de Santé Publique, Centre de Pharmacoépidémiologie (Cephepi), Unité de Recherche Clinique PSL-CFX, CIC-1901, Sorbonne Université, INSERM,…. Major MEDLINE topics: Domperidone, Parkinson Disease, Antiemetics, Nausea. 38 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: ANSM (Agence National de Sécurité du Médicament), Agence Nationale de Sécurité du Médicament et des Produits de Santé.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Context

After observing increased sudden death risk associated with domperidone use, the European Medicines Agency (EMA) imposed usage restrictions in 2014, limiting age (≤60 years), daily dose (≤30 mg/day), and duration (≤7 days). Nausea commonly occurs as an adverse effect of dopaminergic drugs in Parkinson's disease (PD) patients, with few alternative anti‐emetic options. This study aimed to assess domperidone prescription patterns in French PD patients.

Methods

In this multicenter study, all consecutive PD patients from participating expert centers, hospitals, and private neurologists were included. We documented demographics, clinical data, comorbidities, domperidone use (indication, dose, and duration), and concurrent medications (related to PD or not). Domperidone misuse was assessed based on EMA guidelines.

Results

Between January and October 2021, 1579 patients from 16 centers (12 French PD expert centers, two general hospitals, and two private practice neurologists) were included. Among them, 109 (7%) received domperidone: 32 (29%) for nausea during apomorphine infusion, 71 (65%) for nausea during other dopaminergic therapies, and three (3%) for orthostatic hypotension. Domperidone misuse was found in 103 patients (95%): treatment duration >7 days (84%), age >60 years (79%), contraindicated drug interactions (6%), and contraindications due to cardiac comorbidity (5%). Only one patient exceeded the recommended dose (30 mg/day).

Conclusion

Domperidone is still prescribed in France for PD patients with dopaminergic‐induced nausea, mostly disregarding EMA guidelines due to patient age (>60 years) and prolonged treatment (>7 days). Our study underscores the unmet need for managing gastrointestinal symptoms in PD, highlighting the inadequacy of EMA guidelines in this population.

Subjects

MeSH terms (MEDLINE)

DomperidoneParkinson DiseaseAntiemeticsNauseaPractice Patterns, Physicians'Antiparkinson AgentsDrug MisuseHumansMaleFemaleFranceAgedMiddle AgedAged, 80 and over

Author keywords

European Medicines AgencyParkinson diseasedomperidonemisusenausea

Substances

DomperidoneAntiemeticsAntiparkinson Agents

Authors and institutions

  • Département de Santé Publique, Centre de Pharmacoépidémiologie (Cephepi), Unité de Recherche Clinique PSL-CFX, CIC-1901, Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, équipe PE…
  • Department of Neurology, CIC Neurosciences, NS-PARK/FCRIN Network, Hôpital Pitié-Salpêtrière, Sorbonne Université, Assistance Publique Hôpitaux de Paris, Paris Brain Institute - ICM, Inserm, CRNS, Paris, France.
  • Centre Expert Parkinson and NS-PARK/FCRIN Network, CHU Henri Mondor; AP-HP et Equipe Neuropsychologie Interventionnelle, INSERM-IMRB, Faculté de Santé, Université Paris-Est Créteil et Ecole Normale Supérieure PSL Univer…
  • Service de Neurologie des Maladies Neurodégénératives, IMNc, CHU Bordeaux, Bordeaux, France.
  • CNRS, IMN, UMR 5293, Université de Bordeaux, Bordeaux, France.
  • Department of Medicine, University of Otago, Christchurch, and New Zealand Brain Research Institute, Christchurch, New Zealand.

ORCID profiles: Edouard Januel, Maryse Lapeyre-Mestre

Funding

  • ANSM (Agence National de Sécurité du Médicament)
  • Agence Nationale de Sécurité du Médicament et des Produits de Santé

Cite

APA

Januel, E., Corvol, J. C., Remy, P., Meissner, W. G., Thiriez, C., Lanore, A., Bonnet, C., Azulay, J. P., Giordana, C., Maltete, D., Frismand, S., Tranchant, C., Sellal, F., Jager, A., Béreau, M., Castelnovo, G., Vallet, A. E., Lapeyre-Mestre, M., Turc, J. D., …, & DUMP study group (2025). Use and misuse of domperidone in patients living with Parkinson disease in France. Fundamental & Clinical Pharmacology. https://doi.org/10.1111/fcp.70002

Vancouver

Januel E, Corvol JC, Remy P, Meissner WG, Thiriez C, Lanore A, et al. Use and misuse of domperidone in patients living with Parkinson disease in France. Fundamental & Clinical Pharmacology. 2025. doi:10.1111/fcp.70002

BibTeX
@article{Januel2025,
  author = {Januel, Edouard and Corvol, Jean Christophe and Remy, Philippe and Meissner, Wassilios G and Thiriez, Claire and Lanore, Aymeric and Bonnet, Cecilia and Azulay, Jean-Philippe and Giordana, Caroline and Maltete, David and Frismand, Solene and Tranchant, Christine and Sellal, Francois and Jager, Alain and Béreau, Matthieu and Castelnovo, Giovanni and Vallet, Anne Evelyne and Lapeyre-Mestre, Maryse and Turc, Jean-Denis and Rascol, Olivier and Tubach, Florence and DUMP study group, DUMP study group},
  title = {Use and misuse of domperidone in patients living with Parkinson disease in France},
  journal = {Fundamental & Clinical Pharmacology},
  year = {2025},
  doi = {10.1111/fcp.70002}
}
Start for free →